SecBot SecBot
8-K ·Filed Jun 11, 2026

INGN

Inogen Inc
NEUTRAL
Impact 3/10
Horizonweeks Processed4mo ago SEC0001294133-26-000021
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

This is a routine administrative filing from the annual meeting. No immediate trading action warranted. Monitor future equity grant disclosures for potential dilution impact.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
INGN ▼ -18.28% at T+60d
NEUTRAL call -18.28% · α vs SPY -21.55% · entry $6.40 → $5.23
Entry = T+0 close
Jun 11, 2026
via day close
T+1d
+0.94%
call +0.94% · α -0.83%
$6.46
settled 5mo ago
T+5d
+0.16%
call +0.16% · α -0.52%
$6.41
settled 4mo ago
T+20d
+2.19%
call +2.19% · α +0.41%
$6.54
settled 4mo ago
T+60d
-18.28%
call -18.28% · α -21.55%
$5.23
settled 7w ago

Price Chart

Loading chart...

Executive Summary

Inogen shareholders approved the Amended and Restated 2023 Equity Incentive Plan at the annual meeting on June 5, 2026, increasing the share reserve by 750,000 shares. Routine governance update with no material financial impact.

Key Facts

  • Shareholders approved the Amended and Restated 2023 Equity Incentive Plan with 16,208,966 votes for, 2,009,937 against, and 54,322 abstentions
  • The plan amendment adds 750,000 shares to the equity incentive pool
  • Class III directors Glenn Boehnlein and Mira Sahney were elected
  • Deloitte & Touche LLP ratified as auditor for FY2026
  • Advisory vote on executive compensation passed with 17,316,134 votes for
  • Proposal to declassify the board did not pass (17,883,761 for, but required supermajority under existing charter)
  • Approximately 76.28% of outstanding shares were represented at the meeting

Financial Impact

Dilution of approximately 2.7% from 750,000 additional shares authorized under the equity plan

dilution

Risk Factors

  • Potential dilution from future equity grants under the expanded plan
  • Board declassification failure may signal governance concerns to some investors

Market Snapshot

Exchange
Nasdaq
Sector
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001294133-26-000021
Document: ingn-ex10_4.htm0001294133-26-000021
Document: ingn-ex10_3.htm0001294133-26-000021
Document: ingn-ex10_2.htm0001294133-26-000021
Document: ingn-20260605.htm0001294133-26-000021
Document: 0001294133-26-000021-index-headers.html0001294133-26-000021
Document: 0001294133-26-000021-index.html0001294133-26-000021
Document: 0001294133-26-000021.txt0001294133-26-000021
3 reports for INGN
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for INGN — sortable, filterable
TypeNow
Jun 11, 2026
19w ago
8-K
NEUTRAL ★ 3/10
$6.40 $5.23▼ −18.28%▼ −21.55%$7.14 (+11.56%)
Apr 6, 2026
29w ago
8-K
NEUTRAL ★ 6/10
$6.80 $6.60▼ −2.94%▼ −16.21%$7.14 (+5.00%)
Feb 24, 2026
34w ago
8-K
BULLISH ★ 7/10
$6.01 $6.34▲ +5.49%▼ −1.46%$7.14 (+18.80%)
Showing 3 of 3

US Market Status

Market Open — Closes in 5h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 11, 2026